Repro Historical Balance Sheet
KRMD Stock | USD 3.66 0.14 3.98% |
Trend analysis of Repro Med Systems balance sheet accounts such as Cash of 12.1 M provides information on Repro Med's total assets, liabilities, and equity, which is the actual value of Repro Med Systems to its prevalent stockholders. By breaking down trends over time using Repro Med balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Repro Med Systems latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Repro Med Systems is a good buy for the upcoming year.
Repro Med Inventory |
|
Repro |
About Repro Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Repro Med Systems at a specified time, usually calculated after every quarter, six months, or one year. Repro Med Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Repro Med and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Repro currently owns. An asset can also be divided into two categories, current and non-current.
Repro Med Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Repro Med assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Repro Med Systems books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Repro Med balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Repro Med Systems are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most accounts from Repro Med's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Repro Med Systems current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, Repro Med's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 4.7 M, whereas Retained Earnings are projected to grow to (22.1 M).
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 604.1K | 4.9M | 4.4M | 4.7M | Total Assets | 41.3M | 42.3M | 28.5M | 29.9M |
Repro Med balance sheet Correlations
Click cells to compare fundamentals
Repro Med Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Repro Med balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.9M | 39.9M | 41.3M | 42.3M | 28.5M | 29.9M | |
Total Current Liabilities | 2.4M | 3.7M | 4.8M | 7.0M | 4.5M | 4.7M | |
Net Debt | (5.5M) | (27.1M) | (24.7M) | (12.5M) | (7.0M) | (6.7M) | |
Retained Earnings | 4.9M | 3.7M | (910.1K) | (9.6M) | (23.3M) | (22.1M) | |
Cash | 5.9M | 27.3M | 25.3M | 17.4M | 11.5M | 12.1M | |
Non Current Assets Total | 2.0M | 2.4M | 4.0M | 12.5M | 8.2M | 8.6M | |
Net Receivables | 3.2M | 2.6M | 4.3M | 4.5M | 4.1M | 4.3M | |
Common Stock Total Equity | 422.4K | 466.8K | 480.4K | 488.6K | 561.9K | 373.2K | |
Liabilities And Stockholders Equity | 13.9M | 39.9M | 41.3M | 42.3M | 28.5M | 29.9M | |
Non Current Liabilities Total | 239.5K | 95.6K | 1.9M | 4.0M | 3.7M | 3.8M | |
Inventory | 2.4M | 6.8M | 6.1M | 6.4M | 3.5M | 3.7M | |
Total Liab | 2.6M | 3.8M | 4.8M | 11.0M | 8.1M | 8.5M | |
Property Plant And Equipment Gross | 985.6K | 1.2M | 1.2M | 7.7M | 10.1M | 10.6M | |
Total Current Assets | 11.9M | 37.5M | 37.3M | 29.8M | 20.3M | 21.3M | |
Intangible Assets | 807.1K | 843.6K | 808.8K | 787.2K | 754.4K | 792.1K | |
Other Current Liab | 1.7M | 2.8M | 5.6M | 3.7M | 2.7M | 2.8M | |
Total Stockholder Equity | 11.2M | 36.2M | 36.5M | 31.3M | 20.4M | 21.4M | |
Property Plant And Equipment Net | 985.6K | 1.4M | 1.2M | 7.7M | 7.4M | 7.7M | |
Accounts Payable | 572.7K | 624.9K | 1.2M | 2.4M | 975.2K | 502.6K | |
Cash And Short Term Investments | 5.9M | 27.3M | 25.3M | 17.4M | 11.5M | 12.1M | |
Common Stock Shares Outstanding | 39.1M | 41.9M | 44.4M | 45.0M | 45.6M | 37.4M | |
Other Current Assets | 387.4K | 807.8K | 3.1M | 2.9M | 1.2M | 1.3M | |
Other Stockholder Equity | 5.9M | 32.0M | 36.9M | 40.4M | 43.2M | 45.3M | |
Common Stock | 422.4K | 466.8K | 480.4K | 488.6K | 490.9K | 395.6K | |
Net Tangible Assets | 10.4M | 35.3M | 35.7M | 30.5M | 35.1M | 19.3M | |
Other Assets | 207.8K | 381.9K | 2.0M | 4.1M | 4.7M | 4.9M | |
Capital Surpluse | 6.3M | 35.9M | 40.8M | 44.3M | 50.9M | 53.4M | |
Property Plant Equipment | 985.6K | 1.4M | 1.2M | 3.9M | 4.5M | 4.7M | |
Net Invested Capital | 11.2M | 36.2M | 37.0M | 31.8M | 20.7M | 26.7M | |
Capital Stock | 422.4K | 466.8K | 480.4K | 488.6K | 490.9K | 505.7K | |
Net Working Capital | 9.5M | 33.9M | 32.5M | 22.8M | 15.8M | 22.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.26) | Revenue Per Share 0.674 | Quarterly Revenue Growth 0.215 | Return On Assets (0.14) |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.